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Focusing only on cases and 
deaths hides the pandemic’s 
lasting health burden 
on people, societies and 
economies.
The COVID-19 pandemic is well into its second year, but countries are only beginning to grapple with the lasting health crisis. In March, a UK consortium reported that 1 in 5 peo-
ple who were hospitalized with the disease 
had a new disability after discharge1. A large 
US study found similar effects for both hospi-
talized and non-hospitalized people2. Among 
adults who were not hospitalized, 1 in 10 have 
ongoing symptoms 12 weeks after a positive 
test3. Treatment services for the long-term 
consequences of COVID-19 are already having 
to be absorbed into health and care systems 
urgently. Tackling this requires a much clearer 
picture of the burden of the disease than 
currently exists.
Tracking disease cases and deaths has advan-
tages in a health emergency — they are easily 
collated, and, to some extent, trends can be 
compared across countries. But continuing 
the use of such simplified metrics heightens 
the risks of underestimating the true health 
impact on a population. It focuses policy and 
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public discourse on the immediate prevention 
of deaths and on the economic impact of 
lockdown policies, ignoring the long-term 
disease-related disabilities that will also affect 
well-being and productivity. 
To tackle the pandemic’s inequitable impact, 
researchers must also count how COVID-19 
contributes to ill health, and do so compre-
hensively. If scarce resources are allocated 
with only the death count in mind, low- and 
middle-income countries (LMICs) with younger 
populations might not receive their fair share. 
This could be devastating for countries that 
rely on the productivity of people of working 
age for economic development. Choosing 
the right metrics can also help to identify and 
address inequity within countries. Evidence 
from many nations suggest that members of 
minority ethnic communities are more likely to 
catch COVID-19 and die from it, as well as being 
more likely to die at a younger age4 (see also 
Nature 592, 674–680; 2021). 
Fortunately, metrics of illness exist. They 
inform much health policy — from cancer 
screening and treatment to attempts to 
eradicate tuberculosis. Called DALYs and 
QALYs (disability-adjusted life years and 
quality-adjusted life years), these measures 
capture the impact of ill health on a person’s 
life course — combining the years of life lost 
because of premature death, and the years 
lived while experiencing the disabling conse-
quences of disease. 
As health economists, we use these metrics 
to understand the global burden of disease. 
They help us to compare the effects of preven-
tion, treatment and social action (such as edu-
cation or housing initiatives) on tackling the 
HIV pandemic, for example. In a recent study5, 
we used these metrics to estimate that a death 
from COVID-19 results in around 5 QALYs lost, 
on average. We have previously used similar 
estimates to inform COVID-19 vaccine policy 
in the United Kingdom6. 
Here we offer a very rough first estimate, 
based on simple assumptions, that as much as 
30% of the COVID-19 health burden could be 
due to COVID-induced disability, not death. 
Much more needs to be done to improve such 
estimates so they can be acted on effectively. To 
design the right policies now, and invest well to 
deal with COVID-19 (and other pandemics) in 
the future, we need to use metrics that encap-
sulate all the consequences of a disease. 
Long view
Health comprises our social, mental and 
physical well-being. DALYs and QALYs are 
already used by global institutions and 
national governments to capture this holistic 
understanding of the burden of other diseases 
globally.
One DALY represents one year of healthy 
life lost because of illness, disability or early 
death. This metric has been developed and 
used widely by the World Bank, the World 
Health Organization (WHO) and the Uni-
versity of Washington’s Institute for Health 
Metrics and Evaluation (IHME) in Seattle. The 
latter produces annual estimates of the global 
burden of disease (see, for example, ref. 7). 
DALYs are often used by governments in LMICs 
to set priorities across their health sectors. 
A 2020 estimate by Pakistan’s health-services 
ministry found that the cost of a skilled atten-
dant who can manage labour and delivery in 
low-risk pregnant women is just US$2 for each 
DALY averted, for example8. 
One QALY equates to one year of perfect 
health. This measure is mainly used by 
high-income countries (HICs), including the 
United States. That said, the US Affordable 
Care Act of 2010 outlawed the use of QALYs 
following lobbying9. In many countries, the 
metric is often used to assess the value of new 
technologies, such as population screening 
tests or innovative cell and gene therapies. 
Each measure is calculated by considering 
the overall impact of different types of ill 
health — such as cancer or diabetes — during 
the course of a life. Although the detailed meth-
ods of calculating QALYs and DALYs differ, they 
can be considered functionally equivalent.
For instance, a person with a fractured limb 
might recover quickly if they are in their twen-
ties. The same accident could leave a 70-year-
old with reduced mobility for the rest of their 
life. More QALYs are lost and DALYs incurred 
in the second case. Likewise, the burden of 
HIV infection can be vastly reduced if effec-
tive drugs allow a person with the virus to live 
a full life. 
The wide range of COVID-19 outcomes can 
lead to markedly different profiles (see ‘COVID 
casts a long shadow’). A mild case of the dis-
ease in an otherwise well person might lead 
to ‘long COVID’ — a sharp decrease in overall 
health that can resolve after months or last for 
more than a year. Some people with COVID-19 
experience strokes or become diabetic. Weeks 
of treatment in intensive care can mean that 
a person never returns to their former health 
because of damage to the brain, heart or lungs, 
for example. More needs to be understood 
about all of these scenarios so that researchers 
can calculate disease burdens with confidence.
COVID burdens
To illustrate how QALYs and DALYs can pro-
vide a more complete picture of COVID-19, we 
attempted a first rough estimate of the burden 
of the disease in two countries that have dif-
ferent demographics: Pakistan and the United 
COVID CASTS A LONG SHADOW
Conditions such as heart disease gradually decrease a person’s quality of life (blue) and increase their disability 
burden (pale orange) over their lifetime. Catching COVID-19 adds an immediate disability burden (dark orange). 









1. Long COVID with
eventual return
to initial health
2. Long COVID with
persistent fatigue
over lifetime
3. Severe COVID-19 
with hospitalization and
stroke that requires lifelong care













“Improved measures of 
disease burden can help to 
map the impact of COVID-19 
on vulnerable communities.”
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LIFE AND HEALTH LOST
Metrics that capture the overall burden of ill health, rather than simply counting deaths, hint at how 
COVID-19 might aect populations in Pakistan and the United Kingdom in the long term.
Dierent demographics
Pakistan’s population is predominantly young; the United Kingdom’s 










DALYs lost to COVID-19
Estimates using disability-adjusted life years (DALYs) suggest that, in Pakistan, 
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Kingdom (see ‘Life and health lost’). The pop-
ulation of Pakistan, in common with many 
LMICs, has a high proportion of younger age 
groups; the United Kingdom, like other HICs, 
does not. It should be noted that our sketch is 
illustrative only, because we extrapolated from 
UK data on the rates of hospitalized people 
needing long-term care. The two nations have 
differing health systems, pre-existing patterns 
of co-morbidity and so on; and many people 
who are not hospitalized with COVID-19 also 
experience lasting effects. 
We approximate that the health burden 
due to COVID-induced disability across all 
age groups could be around 30% overall. We 
arrived at this crude figure using modest 
assumptions about the duration and severity 
of COVID-19-related disease (see Supplemen-
tary information). This number also assumes 
a loss of 0.5 DALYs for an average case of long 
COVID, regardless of age, and includes DALYs 
lost as a result of COVID-19 deaths, using stand-
ard methods5.
This exercise hints at how much of the long-
term health impact we could be missing by 
counting only deaths. 
We can also compare the DALYs lost across 
age groups. The demographics in Pakistan 
could place more of the estimated burden 
of sickness on people of working age. More 
research is needed to assess whether this is the 
case: death statistics, in particular, could be 
under-reported among older people in many 
countries. 
In the United Kingdom, too, counting COVID 
disabilities gives a different picture of the 
impact of the pandemic. The steep increase 
in death rate with age means that deaths dom-
inate the DALYs lost for the very old. But the 
share of cases is much flatter across the adult 
population. Younger people are much more 
likely to be left sick than dead by COVID-19. 
Metrics that consider a person’s stage of life 
and disease could fundamentally shift both 
public understanding and the policy response 
to COVID-19.
Metrics for policy
QALYs and DALYs enable governments to 
balance resources between lockdowns, 
quarantine, social distancing, ventilation, 
masking, vaccination, testing, treatment 
and long-term care for COVID-19. It is cru-
cial to get these trade-offs right in LMICs 
such as Pakistan, where the public purse has 
only US$15 per person to spend on health, 
according to World Bank data. The price of 
COVID-19 vaccination is considerable. The 
cost of administering two doses of COVID-19 
vaccine in Pakistan is estimated to be $3.15 
per person, without factoring in the cost of 
the doses themselves10.
As the market for COVID-19 vaccines and 
therapeutics becomes more crowded, using a 
common metric for disease burden and value 
assessment will become important for HICs, 
too. It seems self-evident that vaccines are a 
wise investment for wealthy nations, given the 
huge toll that the pandemic places on econo-
mies. Indeed, for this reason, we think it might 
be cost-effective for HICs to vaccinate the 
entire global population, not just their own 
citizens. But countries could have to decide, 
for example, whether the antibody cocktail 
casirivimab and imdevimab is a sensible use of 
heath budgets, now that data are emerging on 
its potential effectiveness and before a price 
has been set (see go.nature.com/3wh9kjy). 
An estimated 6% of the global population is 
living with two or more conditions (co-mor-
bidities) that put them at high risk of death 
or disability from COVID-19 (ref. 11). QALYs 
and DALYs can help governments to compare 
interventions targeted at such co-morbidities 
with those that directly address COVID-19. 
For instance, managing non-communicable 
diseases such as diabetes requires substantial 
increases in funding globally12. Without a clear 
analysis of these factors, pressure to allocate 
scarce resources to COVID-19 could reduce the 
availability of services for non-communicable 
disease. This might worsen overall well-being 
in the long run13. 
Improved measures of disease burden 
can help to map the impact of COVID-19 
on vulnerable communities. In the United 
States, Black and Latinx people and Indig-
enous Americans are roughly three times 
more likely to be hospitalized with the dis-
ease than are white or Asian, non-Hispanic 
people (Nature 592, 674–680; 2021).
Longer-term outcomes are also likely to 
be affected by underlying health disparities 
and unequal access to care and treatment. 
And for people without a social safety net, 
chronic disease can push them into poverty14.
Metrics that capture how ill health, 
disability, stigma and poverty interact with 
COVID-19 could prove pivotal in efforts to 
overcome the disease. Other infectious 
diseases, such as tuberculosis, commonly 
become entrenched in communities that are 
unable to fully protect themselves against 
risk, owing to social and economic barriers14. 
“Younger people are much 
more likely to be left sick 
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In the ongoing global HIV epidemic, coun-
tries that recognized and supported com-
munity action for vulnerable people15 early 
on were able to prevent wider transmission 
over time. 
Next steps 
It has always been difficult to assess the com-
prehensive burden of health and inequity. This 
is particularly hard in settings where disease 
surveillance and health-information systems 
are weak. The COVID-19 pandemic has shown 
the importance of these systems, and should 
drive a global effort to improve them. 
Poorer nations are streets ahead of wealthy 
ones in their use of DALYs. The metric has 
highlighted emerging patterns of HIV in 
south India, for example, and has helped to 
identify the risk factors behind them16. They 
also inform health planning. Ethiopia17 and 
Pakistan both recently used DALYs to define 
the package of services required to roll out 
universal health care in their countries. 
On the basis of this infrastructure, global 
DALYs attributable to COVID-19 are likely to 
appear in the next burden of disease estimates 
from both the WHO and the IHME. Due to be 
released in the second half of 2021, these 
should be the first comprehensive assess-
ments of the relative health burden from 
COVID-19 globally. They could support the 
change in measurement and perception that 
we are highlighting, but they are likely to suffer 
from a paucity of data, with estimates being 
highly uncertain. 
These data gaps appear because many 
LMICs lack the reporting infrastructure 
required to calculate QALYs and DALYs. 
Apart from South Africa, most countries in 
sub-Saharan Africa have been unable to count 
excess deaths from COVID-19, for example, 
because of inadequate registration systems. 
Scaling up of testing remains one of the most 
urgent public-health needs. But it is challeng-
ing for governments to prioritize the gather-
ing of information when they cannot afford 
essential medicines18. The scientific commu-
nity and HICs should ramp up investment in 
health information systems to capture service 
use, morbidity and mortality. 
Research funding to build a global picture 
of COVID-19-related disease is also needed. 
The full range of symptoms and conse-
quences is not yet known. These might also 
depend on a person’s underlying health status 
and access to care. Longitudinal studies, sim-
ilar to those beginning to report in the United 
Kingdom1 and other HICs19, 20, should be initi-
ated globally. These should assess the men-
tal-health effects and long-term economic 
impacts of living with chronic diseases in the 
wake of COVID-19. Countries such as South 
Africa — which developed infrastructure to 
track populations over time for epidemics 
such as HIV — should lead the way. 
Data on both deaths and disease in vul-
nerable groups is often the most challeng-
ing to collect, particularly where access to 
services is poor. But it can be done. Kenya, for 
instance, is already conducting surveys that 
can potentially feed into real-time models of 
COVID-19 transmission and impact21. These 
should be linked with burden-of-disease 
estimates. 
As we count the devastating losses from 
COVID-19 — of loved ones, jobs, communities, 
security — the lasting loss of health must also 
be tallied. Without the right metrics, we can 
see, understand and respond to only a fraction 
of the problem.
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